ChIP assay result validated that the constitutively activated signal transducer and activator of transcription 3 (STAT3) directly targets and activates pri-miR-21 in Sézary Syndrome (SS), a cutaneous T-cell lymphoma (CTCL) [26]. This evidence concerns the gene STAT3 and primary cutaneous T-cell non-Hodgkin lymphoma.